- Home
- UTHR vs FFIV Comparison
UTHR vs FFIV Comparison
Compare UTHR & FFIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UTHR
- FFIV
- Stock Information
- Founded
- UTHR 1996
- FFIV 1996
- Country
- UTHR United States
- FFIV United States
- Employees
- UTHR N/A
- FFIV N/A
- Industry
- UTHR Biotechnology: Pharmaceutical Preparations
- FFIV Computer Communications Equipment
- Sector
- UTHR Health Care
- FFIV Telecommunications
- Exchange
- UTHR Nasdaq
- FFIV Nasdaq
- Market Cap
- UTHR 14.4B
- FFIV 14.8B
- IPO Year
- UTHR 1999
- FFIV 1999
- Fundamental
- Price
- UTHR $306.97
- FFIV $263.88
- Analyst Decision
- UTHR Buy
- FFIV Hold
- Analyst Count
- UTHR 12
- FFIV 10
- Target Price
- UTHR $388.25
- FFIV $289.00
- AVG Volume (30 Days)
- UTHR 492.5K
- FFIV 571.6K
- Earning Date
- UTHR 04-30-2025
- FFIV 04-28-2025
- Dividend Yield
- UTHR N/A
- FFIV N/A
- EPS Growth
- UTHR 24.38
- FFIV 31.07
- EPS
- UTHR 24.64
- FFIV 10.05
- Revenue
- UTHR $2,877,400,000.00
- FFIV $2,890,012,000.00
- Revenue This Year
- UTHR $11.70
- FFIV $9.02
- Revenue Next Year
- UTHR $6.50
- FFIV $4.01
- P/E Ratio
- UTHR $12.40
- FFIV $26.26
- Revenue Growth
- UTHR 23.63
- FFIV 3.02
- 52 Week Low
- UTHR $221.53
- FFIV $159.01
- 52 Week High
- UTHR $417.82
- FFIV $313.00
- Technical
- Relative Strength Index (RSI)
- UTHR 39.02
- FFIV 38.14
- Support Level
- UTHR $308.43
- FFIV $270.36
- Resistance Level
- UTHR $318.40
- FFIV $278.85
- Average True Range (ATR)
- UTHR 9.26
- FFIV 6.92
- MACD
- UTHR 1.20
- FFIV 0.43
- Stochastic Oscillator
- UTHR 29.88
- FFIV 35.47
About UTHR United Therapeutics Corporation
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
About FFIV F5 Inc.
F5 is a market leader in the application delivery controller market. The company sells products for security, application performance, and automation. Its three customer verticals are enterprises, service providers, and government entities. Revenue is evenly split between its services business and products business with revenue trending toward products due to software adoption. The Seattle-based firm was incorporated in 1996, and went public in 1999.